We use cookies to help provide you with the best possible online experience. Learn more

    Interim report January 1 - September 30, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In the first nine months of the year, net sales rose 12 percent to SEK 380 M (340). The operating margin declined to 16 percent (29) due to lower growth for RayStation®, negative currency effects due to the weakening of the USD and higher costs due to the company’s investments in the global marketing organization and in research and development. The development of RayCare® is continuing as planned,” says Johan Löf, President and CEO of RaySearch. 

    THIRD QUARTER (JULY-SEPTEMBER 2017) 

    • Net sales SEK 111.7 M (125.7), of which revenues from RayStation SEK 99.1 M (112.6)  
    • Loss after tax SEK 1.0 M (profit: 28.9) and loss per share before/after dilution SEK 0.03 (earnings: 0.84) 
    • Operating profit SEK 0.7 M (38.5) 
    • Cash flow SEK 1.2 M (neg: 4.2) 
    • Order intake excl. service agreements SEK 102.0 M (101.1), of which RayStation SEK 92.8 M (91.2) 
    • At the end of the period, the order backlog for RayStation was SEK 39.1 M (55.5)

    NINE MONTHS (JANUARY-SEPTEMBER 2017) 

    • Net sales SEK 380.1 M (340.1), of which revenues from RayStation SEK 339.1 M (301.2)  
    • Profit after tax SEK 45.3 M (75.5) and earnings per share SEK 1.32 (2.20) 
    • Operating profit SEK 60.9 M (99.3) 
    • Cash flow negative SEK 15.5 M (neg: 30.4) 
    • Order intake excl. service agreements SEK 315.7 M (312.1),of which RayStation SEK 284.6 M (284.6)

    SIGNIFICANT EVENTS DURING THE THIRD QUARTER

    • RayStation was selected by a number of leading cancer clinics, for example, CYCLHAD Hadrontherapy Center in France, OLVZ Aalst in Belgium and the University of Tsukuba in Japan. RayStation was also chosen by the University of Wisconsin-Madison and the Provision CARES proton therapy center in Nashville in the US. Provision CARES will be the first clinical ProNova proton system in the world. 
    • A long-term collaborative agreement for RayCare* was signed with Provision Healthcare in the US.
    • A partnership was also initiated with Neutron Therapeutics in the US and Sumitomo Heavy Industries in Japan for treatment planning for boron neutron capture therapy (BNCT).

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 22, 2017 at 7:45 a.m. CET.  

    FOR FURTHER INFORMATION, PLEASE CONTACT: 

    Johan Löf, President and CEO Tel: +46 8 510 530 00 E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO   
    Tel: +46 70 661 05 59  
    E-mail: peter.thysell@raysearchlabs.com

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com. 

    * Regulatory approval is required in some markets.

    PDF

    Interim report Janury 1 - September 30, 2017

    PDF

    RaySearch Laboratories AB (publ)

    THIRD QUARTER (JULY-SEPTEMBER 2017) 

    • Net sales SEK 111.7 M (125.7), of which revenues from RayStation SEK 99.1 M (112.6)  
    • Loss after tax SEK 1.0 M (profit: 28.9) and loss per share before/after dilution SEK 0.03 (earnings: 0.84) 
    • Operating profit SEK 0.7 M (38.5) 
    • Cash flow SEK 1.2 M (neg: 4.2) 
    • Order intake excl. service agreements SEK 102.0 M (101.1), of which RayStation SEK 92.8 M (91.2)  
    • At the end of the period, the order backlog for RayStation was SEK 39.1 M (55.5)

    NINE MONTHS (JANUARY-SEPTEMBER 2017) 

    • Net sales SEK 380.1 M (340.1), of which revenues from RayStation SEK 339.1 M (301.2)  
    • Profit after tax SEK 45.3 M (75.5) and earnings per share SEK 1.32 (2.20) 
    • Operating profit SEK 60.9 M (99.3) 
    • Cash flow negative SEK 15.5 M (neg: 30.4)  
    • Order intake excl. service agreements SEK 315.7 M (312.1), of which RayStation SEK 284.6 M (284.6)

    SIGNIFICANT EVENTS DURING THE THIRD QUARTER 

    • RayStation was selected by a number of leading cancer clinics, for example, CYCLHAD Hadrontherapy Center in France, OLVZ Aalst in Belgium and the University of Tsukuba in Japan. RayStation was also chosen by the University of Wisconsin-Madison and the Provision CARES proton therapy center in Nashville in the US. Provision CARES will be the first clinical ProNova proton system in the world.  
    • A long-term collaborative agreement for RayCare* was signed with Provision Healthcare in the US. 
    • A partnership was also initiated with Neutron Therapeutics in the US and Sumitomo Heavy Industries in Japan for treatment planning for boron neutron capture therapy (BNCT).

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on
    November 22, 2017 at 7:45 a.m. CET.  

    FOR FURTHER INFORMATION, PLEASE CONTACT: 

    Johan Löf, President and CEO Tel: +46 8 510 530 00   
    E-mail: johan.lof@raysearchlabs.com
    Peter Thysell, CFO     Tel: +46 70 661 05 59
    E-mail: peter.thysell@raysearchlabs.com

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com. 

    * Regulatory approval is required in some markets. 

    PDF

    RAYSEARCH ENTERS AGREEMENT WITH SUMITOMO FOR BORON NEUTRON CAPTURE THERAPY

    PDF

    RaySearch and Sumitomo Heavy Industries, Ltd. (Sumitomo), based in Tokyo, Japan, have entered into an agreement regarding treatment planning for boron neutron capture therapy (BNCT) – a unique type of radiation therapy that targets cancer at the cellular level. The agreement extends the existing cooperation between Sumitomo and RaySearch on proton therapy.

    Sumitomo has developed the world’s first accelerator-based clinical BNCT system and is conducting clinical trials regarding recurrent head-and-neck and brain cancers in Japan.  Treatment planning is an essential aspect of BNCT, and Sumitomo selected RayStation because of its advanced capabilities and usability.

    Under the agreement, RayStation’s functionality will be extended to support BNCT planning requirements*. BNCT will be an additional treatment modality in RayStation, alongside the existing options for photon, electron, proton, and carbon ion therapy. Users of BNCT will have access to the full range of advanced functionality in RayStation, including atlas-based segmentation, deformable image registration and scripting.

    BNCT is a promising radiation therapy technique based on a two-step process. First, the patient is injected with a tumor-localizing drug containing the non-radioactive isotope boron-10. In the second step, the target area is exposed to a beam of low-energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction in which short-range, high-energy charged particles are emitted. These particles systematically destroy the tumor cells, with minimal damage to adjacent healthy tissue.

    Tetsuya Okamura, Senior Vice President and General Manager Industrial Equipment Division at Sumitomo, says: “We are very pleased to work with RaySearch in developing future technologies such as BNCT.  This is an emerging treatment method, and there is still a long way to go, but I believe our collaboration will accelerate commercialization of the modality and provide great benefits for cancer patients and hospitals.”

    Johan Löf, CEO of RaySearch, says: “RaySearch is committed to supporting cutting-edge techniques and approaches that have the potential to improve cancer treatment. This agreement presents exciting new possibilities, and we look forward to exploring the clinical possibilities of BNCT together with Sumitomo.”

    About Sumitomo Heavy Industries, Ltd.
    Sumitomo Heavy Industries, Ltd. is a technology-oriented Japanese manufacturer of medical equipment and industrial machinery. Its accelerator technology is widely used in the semiconductor industry, the nuclear physics research sector, and in medical applications for diagnostic and therapeutic use.  The company has approximately 19,300 employees worldwide and is listed on the Tokyo Stock Exchange.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets

    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    Shin Masui, Product Manager, Sumitomo Heavy Industries, ltd.
    Telephone: +1 610 791 6716
    shin.masui@shi-g.com

    PDF

    Leading Belgian hospital OLVZ selects RayStation

    PDF

    OLV Ziekenhuis (OLVZ) is among the 10 largest hospitals in Belgium and offers a full range of specialties, including cancer treatment. To stay at the cutting edge in radiation therapy, the hospital needed a new treatment planning system for its largest campus at Aalst. RayStation was selected following an extensive evaluation of the leading systems.

    RayStation scored very highly on all of the hospital’s key selection criteria, which included fast calculation speed, automation capabilities, adaptive planning and a user-friendly interface. It will now consolidate and replace a number of different treatment planning systems that are currently in use at OLVZ. The RayStation purchase comprises a comprehensive set of features, including multi-criteria optimization, VMAT, IMRT, electron planning, fallback planning, automated breast planning, adaptive therapy, scripting and contouring.

    Dr. Samuel Bral, Radiation Oncologist at OLVZ, says: “We selected RayStation as our new platform for registration of images and delineation to allow us to use more advanced tools for image registration, auto-segmentation and manual contouring. These tools will enable us to introduce new treatment approaches such as a plan-of-the-day approach and adaptive radiation therapy. This patient-centered approach will ensure we are a community cancer center that provides access to the highest quality treatment.”

    Dr. Nadine Linthout, Physicist at OLVZ, says:
    “RayStation is a highly developed treatment planning system that supports the use of templates, protocols, scripting and automated planning. These are tools we need in order to introduce more efficient workflows and increase the user-independence of treatment planning. RayStation will help us to ensure high quality plans for our patients.”

    Johan Löf, CEO of RaySearch, says: “We are very pleased to help OLVZ stay at the forefront of radiation therapy. The hospital’s requirements are an excellent match for RayStation’s high speed, workflow automation capabilities, unmatched support for adaptive therapy and compatibility with a wide range of treatment machines. We look forward to supporting OLVZ long into the future.”

    About OLVZ
    OLVZ is a major Belgian hospital with campuses located at Aalst, Asse and Ninove. With 959 beds and more than 90,000 admissions per year, it is one of the largest non-university hospitals in Flanders. OLVZ has over 2,500 staff and more than 300 doctors and independent care professionals, making it one of the largest employers in the region. The hospital is known for its cardiology and cardiovascular surgery services, and is also one of the leading players in Belgium in the field of robotic surgery.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.


    To learn more about RaySearch, go to:
    www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.


    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    Raysearch enters into the field of Boron Neutron Capture Therapy

    PDF

    RaySearch and Neutron Therapeutics, Inc., based in Danvers, US, have entered into an agreement regarding treatment planning for boron neutron capture therapy (BNCT), which is a unique type of radiation therapy that enables targeting of cancer at the cellular level.

    BNCT uses a two-step process. First, the patient is injected with a tumor-localizing drug containing the non-radioactive isotope boron-10. In the second step, the target area is exposed to a beam of low-energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction in which short-range, high-energy charged particles are emitted. These particles systematically destroy the tumor cells, with minimal damage to adjacent healthy tissue.

    As part of this agreement, RayStation’s functionality will be extended to support BNCT planning requirements*. BNCT will be an additional treatment modality in RayStation, alongside the existing options for photon, electron, proton, and carbon ion* therapy. Users of BNCT will have access to the full range of advanced functionality in RayStation, such as atlas-based segmentation, deformable image registration and scripting.

    Neutron Therapeutics is developing a complete single-room solution for BNCT, including an accelerator-based neutron source, treatment room equipment, and a dose engine interfaced to a RayStation treatment planning system. The first installation of the system will be at Helsinki University Hospital, and the facility is scheduled to open in 2018.

    Theodore Smick, CEO of Neutron Therapeutics, says: “We are glad to have RaySearch as a partner in the effort to create a comprehensive solution and make the benefits of BNCT available to the patients who need it. Clinics that want to adopt this powerful treatment technique will need high-quality, BNCT-specific treatment planning software, which RaySearch can provide.”

    Johan Löf, CEO of RaySearch, says: “We are very pleased to extend RayStation’s capabilities to support BNCT and integrate with Neutron Therapeutics technology. BNCT has great potential and I’m excited to explore the clinical benefits and enable the use of this treatment technique in routine hospital workflow.”

    About Neutron Therapeutics
    Neutron Therapeutics is a medical equipment company that is developing a comprehensive solution for BNCT. The company was founded in 2014, with a mission to apply high-power proton accelerator technology to the challenge of a practical in-hospital neutron source.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm, and the company is listed in the Mid Cap segment on NASDAQ OMX Stockholm.

    * Pending regulatory clearance in some markets

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com
     

    Theodore Smick, CEO, Neutron Therapeutics Inc.
    Telephone: +1 978-325-6081
    ted.smick@nt-bnct.com
     

    PDF

    RayStation selected for Provision Cares Proton Therapy Center in Franklin, US

    PDF

    Provision Healthcare has selected RayStation for external beam planning at the new Provision CARES proton therapy center in Franklin, Tennessee, which is currently under construction. The center forms part of the Provision CARES Cancer Network. 

    The center, which is scheduled to open in 2018, will be the first clinical ProNova proton system in the world, featuring superconducting magnets and advanced imaging capabilities. The new ProNova SC360 machine will be fully supported by both RayStation and RayCare, RaySearch’s new oncology information system, which will be submitted for FDA clearance at the end of 2017.

    RayStation will be used for all external beam treatment planning at the center. The installation will feature a range of advanced functionalities, such as adaptive planning, deformable registration and fallback planning, which allows planning comparisons between modalities.

    David Raubach, Vice President of Business Development at Provision Healthcare, says: “The plan from the beginning was to make this one of the most advanced proton treatment centers in the world from a technology perspective. We are delighted that RaySearch has partnered with us to provide full support for the first and only 360-degree compact system. And we are confident that the combination of RayStation and RayCare with the new ProNova system will provide a unique platform that will set the new standard for effective and efficient treatment processes.”

    Johan Löf, CEO of RaySearch Laboratories, says: “Our philosophy is to support all delivery systems and, more importantly, to optimize their potential. Software is driving innovation in oncology today – through it we create new possibilities and deliver on the promise of new technologies to improve cancer care for patients. We are pleased to be in partnership with Provision at several levels.”

    About the ProNova system
    ProNova, a division of Provision Healthcare, is committed to making proton therapy accessible to a greater number of patients and physicians worldwide. ProNova was founded by former leaders of CTI Molecular Imaging, which brought positron emission tomography (PET) technology out of the laboratory and made it a clinical reality for millions of cancer patients. Today, the same team is redefining cancer treatment once again with the introduction of the first and only superconducting 360-degree compact proton therapy system. It is the only proton therapy system developed in a clinical setting, benefitting from continuous input from physicians, medical physicists and therapists during the course of design and development. The system includes state-of-the-art features such as pencil beam scanning and advanced imaging with cone-beam CT, all in a compact design.

    About Provision Healthcare
    Provision Healthcare, LLC (Provision) was formed in 2005 with the purpose of developing innovative healthcare solutions focused on improving patient care and clinical outcomes and developing support for research, educational and charitable causes. Through the Provision CARES Cancer Network, Provision has unique and comprehensive expertise in proton therapy that distinguishes it from other proton and cancer center developers and operators. The combination of unique expertise and an innovative, entrepreneurial approach continues to propel Provision towards a position of industry leadership in cancer care and proton therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets

     
    For further information, please contact:

    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com
     

    PDF

    RayStation selected for CYCLHAD Hadrontherapy Center, France (Archade program)

    PDF

    Following a competitive tender process, RayStation has been chosen as the treatment planning system for the CYCLHAD Hadrontherapy Center, located in Caen, France. The center is due to open in 2018 and will be France’s third clinical proton therapy center.

    CYCLHAD will deliver proton therapy treatments via IBA’s ProteusOne compact system, with the first patient treatment scheduled to take place in June. The center is owned, operated and managed by SAS CYCLHAD, and treatment will be conducted by the medical teams of Centre François Baclesse, a comprehensive cancer center located in Caen.

    A further phase of expansion is planned for the center, including the installation of the NHa C400 cyclotron system to enable research with carbon ions.

    The RayStation purchase includes the modules for pencil beam scanning, adaptive therapy, biology and patient modeling.

    Philippe Lagalle, CEO of SAS CYCLHAD, says: “As a pioneering center, we need partners who can deliver when it comes to advanced techniques. RaySearch is a world leader in treatment planning for proton therapy and has proven expertise in supporting IBA systems. RayStation’s power and innovative capabilities will help us to ensure world-class treatment and research. We also plan to evaluate the possibilities of the forthcoming RayCare* oncology information system.”

    Johan Löf, CEO of RaySearch, says: “We are proud to support one of France’s first proton centers. Proton therapy is an important focus area for RaySearch. We have a large market share and our success in this area continues to grow. RaySearch has a strong strategic collaboration with IBA, which builds on our joint commitment to taking proton therapy to new levels.”

    About the ARCHADE program
    ARCHADE (Advanced Resource Centre for Hadrontherapy in Europe) is a collaborative initiative to create a European center dedicated to hadron therapy research, development and clinical treatment. The CYCLHAD Hadrontherapy Center, Located in Caen, France, will carry out multidisciplinary research and treat up to 345 patients per year using proton therapy.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    To learn more about RaySearch, go to:  www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RaySearch releases preliminary outcome for the third quarter 2017

    PDF

    RaySearch Laboratories AB (publ) releases preliminary figures for the third quarter of 2017, which appear to be weaker than expected. Net sales for the third quarter of 2017 are expected to amount to SEK 112 M (126) with operating profit of SEK 1 M (38) and cash flow of SEK -1 M (-4).

    The result has been influenced by three main factors:

    -        Weak order intake in Europe, where several major public tenders have been delayed.

    -        Continued weakening of the US dollar, where the company’s revenues have decreased as a consequence of a weaker US dollar, which also caused negative translation effects for balance sheet items.

    -        Increased costs, where the company so far this year, as a conscious effort, has increased the number of employees in the global market organization and in research and development by about 50 percent, which has not yet generated increased order intake.

    “We are in a market with uneven order flows. We feel confident about our long-term strategy, make major investments in our sales and development organizations, and drive the business operations forward with full force. " says Johan Löf, CEO of RaySearch Laboratories AB.

    The above figures are preliminary and a full report for the period January to September 2017 will be released on November 22, 2017 at 07:45 CET as previously announced.

    For further information, please contact:

    Johan Löf, CEO              Telephone: +46 8 510 530 00     Epost: johan.lof@raysearchlabs.com 
    Peter Thysell, CFO         Telephone: +46 70 661 05 59     Epost: peter.thysell@raysearchlabs.com 

    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 13.00 CET on November 1, 2017.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in December 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.  

    For more information about RaySearch, visit www.raysearchlabs.com.

    PDF

    RayStation achives strong presence in Japan market

    PDF

    The RayStation treatment planning system has generated considerable interest in Japan, a major radiation therapy market where advanced techniques are prevalent. RayStation is now well-established in the country and has a strong user base. RaySearch's distributor in Japan received 13 new RayStation orders during the third quarter of 2017.

    Today, a total of 87 radiation therapy centers in Japan are using RayStation clinically. Of the new orders received, 12 were for photon planning and one was for proton planning. Japan is a major pioneer of proton therapy and RayStation has been selected as the treatment planning system in most of the recent procurements.

    RayStation customers in Japan now range from leading university hospitals to smaller regional hospitals. In order to provide optimal support for this important market, RaySearch has established the wholly owned subsidiary RaySearch Japan K.K., based in Tokyo.

    Takeshi Kosuga, Regional Business Director at RaySearch Japan K.K., says: “By establishing this subsidiary, we have strengthened our support for customers in Japan. There is strong demand for the RayStation treatment planning system, and the market has also expressed a great deal of interest in RayCare*, our next-generation oncology information system, which will be released in December 2017."

    Johan Löf, CEO of RaySearch Laboratories, says: “I am delighted that we have been able to achieve such a strong position in Japan. Our distributor has done an excellent job of establishing RayStation in the country, and I am pleased that we can bring the unique benefits of RayStation to this important and sophisticated market.”
     

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RayCare*
    RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
     

    To learn more about RaySearch, go to: www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.
     

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

     

    PDF

    RaySearch completes major expansion of RayStation platform at Princess Margaret Cancer Centre

    PDF

    University Health Network’s Princess Margaret Cancer Centre (PMH) in Toronto, Canada has increased the number of RayStation licenses as part of a phased approach to full implementation of the RaySearch Treatment Planning System. The purchase also includes RayStation’s Plan Explorer functionality, which makes it possible to automatically generate a large number of plans for defined clinical goals and combinations of treatment techniques and machines.

    The purchase covers the core RayStation technologies –3D-CRT, IMRT, VMAT, deformable registration, dose tracking and multi-criteria optimization along with some additional technologies such as radiobiology and virtual simulation. PMH has decided to implement six Plan Explorer licenses to determine how the new technology might further streamline planning, both in terms of automation and exploring possible treatment solutions.

    Dr. Fei-Fei Liu, Chief of the Radiation Medicine Program at PMH says: “The team at Princess Margaret Cancer Centre has done a lot of work and retrospective analyses to determine the best technologies and treatment approaches for the future. We are very optimistic about how we can implement adaptive radiation therapy and further automate treatment planning to optimize our treatment approaches and improve care for our patients. We believe these technologies will continue to allow us to create high quality treatment plans, more efficiently than ever before.”

    Johan Löf, CEO of RaySearch, says: “We have an excellent and longstanding partnership with PMH and I am delighted to be able to support them in developing tomorrow’s cancer treatment approaches. With this agreement, PMH is on the way to being one of the biggest RayStation installations in the world.”

    About Princess Margaret Cancer Centre, University Health Network
    The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to
    www.theprincessmargaret.ca or www.uhn.ca.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    RayCare oncology information system to be shown at ASTRO 2017

    PDF

    During 24–27 September, RaySearch will be exhibiting at the ASTRO 2017, the Annual Meeting of the American Society for Radiation Oncology, in San Diego, US. Among other highlights, the company will present its next-generation oncology information system, RayCare®*, which will be released in December 2017. Attendees are welcome to visit RaySearch at booth #1647 and demonstrations can be booked now at www.raysearchlabs.com.

    The next-generation oncology information system
    RayCare is a machine-learning oncology information system created to support every step of cancer care and enable truly comprehensive treatment organized around each patient’s needs. RayCare integrates seamlessly with RayStation, but that’s just the start. The system is designed to connect all the oncology disciplines, fluidly coordinate tasks and ensure optimal use of resources.

    RayCare will consolidate the multiple software systems that are commonly in use, including systems for medical oncology, radiation oncology and surgical oncology. Integrating the varied activities in these workflows saves time, reduces complexity and minimizes the risk of errors that can occur when transferring information between systems. And with a wide range of data immediately accessible to everyone who needs it, RayCare will bring adaptive treatment within reach for every clinic.

    RayStation 6: harmonizing treatment planning
    The latest RayStation innovations will all be on show at ASTRO. Key features in RayStation 6 include support for TomoTherapy. This addition made RayStation the only system to enable planning for both conventional linacs and TomoTherapy systems, giving one point of control for all treatment planning activities.

    RayStation 6 also features MR-based planning, which makes it possible to use an MR image as the planning image for photon therapy as well as simultaneous optimization of multiple beam sets for SMLC, DMLC and VMAT. Other highlights include Monte Carlo dose calculation for proton pencil beam scanning (PBS) and PBS planning with block apertures.

    Automated planning and Plan Explorer
    RayStation has extensive automated planning features that help optimize workflows and create new treatment possibilities. Plan Explorer, for example, makes it possible to automatically generate a large number of high-quality treatment plan alternatives, saving valuable time and giving the clinician a wide range of options to consider.

    Adaptive therapy
    RayStation is designed to make adaptive therapy easy to implement and perform in clinical practice. At the RaySearch booth, attendees can discover how automation features and smart tools in the fully integrated dose tracking and adaptive planning modules make it straightforward to get started.

    PDF

    Provision Healthcare joins the global association of RayCare clinical partners

    PDF

    Provision, located in Knoxville, Tennessee, is the latest to partner with RaySearch Laboratories on the development of its next-generation oncology information system, RayCare®. The global association of RayCare clinical partners now consists of, in order of entry: UMC Groningen, Iridium Kankernetwerk, UCSF, MD Anderson Cancer Center, University of Wisconsin–Madison and Provision CARES Proton Therapy Centers.

    RaySearch started out with a vision for radiation therapy treatment planning. This became the foundation for the RayStation treatment planning system, which already embodies much of that vision and continues to evolve. But while RayStation provides a comprehensive set of tools and calculation services for treatment planning, the full extent of its possibilities can only be achieved in combination with an equally capable oncology information system. This fact was the starting point for RayCare.

    RaySearch’s clinical partners play a central role in the development of RayCare. They provide input on what an oncology information system should provide for various types of treatments, for different roles within healthcare teams and, ultimately, for patients. This input feeds into RaySearch’s agile development, and new software versions are regularly provided to the partners so they can provide feedback on the implementation.

    The RayCare clinical partners encompass different types of cancer care providers, with varied areas of excellence. Provision brings a strong focus on developing, managing and operating comprehensive cancer centers featuring proton therapy, bringing know-how needed to provide the highest possible quality of cancer care.

    Niek Schreuder, Vice President and Chief Medical Physicist for Provision Healthcare, says: “For Provision, it is of great strategic importance for our Cancer CARE Network to have an integrated and efficient solution for patient treatment and care. RaySearch has the competence and innovative focus that Provision needs, and we share a vision of the future of cancer care.”

    Johan Löf, CEO of RaySearch says: “In 2014, the Provision CARES Proton Therapy Center, Knoxville, became the first center in the world to use RayStation for clinical proton treatments. The Provision team continues to push the frontiers of radiation therapy, and we are proud to have them on board for the development of RayCare.”
     

    About RayCare
    RayCare is a next generation OIS developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    More information about RaySearch is available at www.raysearchlabs.com 

    About Provision Healthcare
    Provision Healthcare, LLC (Provision) was formed in 2005 with the purpose of developing innovative healthcare solutions focused on improving patient care and clinical outcomes and developing support for research, educational and charitable causes. Provision has developed a unique, comprehensive expertise in proton therapy that distinguishes it from other proton and cancer center developers and operators that have a much narrower focus. The combination of unique expertise and an innovative, entrepreneurial approach continues to propel Provision towards a position of industry leadership with respect to both cancer care and proton therapy. 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    or

    Nancy Howard
    Provision Healthcare, Knoxville, TN
    +1 (865) 603-0865 

    nancy.howard@provisionproton.com

    PDF

    Interim report January 1 – June 30, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “In the first half of the year, net sales rose 25 percent to SEK 268 M (214). However, the operating margin declined to 22 percent (28) as a result of currency effects and increased selling expenses due to the expansion of our global sales and support organization. The University of Wisconsin-Madison has become a business partner for RayCare® and development activities are progressing according to plan,” says Johan Löf, President and CEO of RaySearch. 

    SECOND QUARTER (APRIL-JUNE 2017) 

    • Net sales SEK 141.6 M (119.0), of which revenues from RayStation® SEK 127.6 M (107.8)  
    • Profit after tax SEK 20.1 M (28.8), and earnings per share before/after dilution SEK 0.59 (0.84) 
    • Operating profit SEK 26.8 M (37.5) 
    • Cash flow negative SEK 13.7 M (neg: 21.0) 
    • Order intake excl. service agreements SEK 108.8 M (129.1), of which RayStation SEK 98.0 M (120.8)  
    • At the end of the period, the order backlog for RayStation was SEK 36.0 M (65.2)

    HALF-YEAR (JANUARY-JUNE 2017) 

    • Net sales SEK 268.4 M (214.4), of which RayStation SEK 240.0 M (188.6)  
    • Profit after tax SEK 46.4 M (46.6) and earnings per share SEK 1.35 (1.36) 
    • Operating profit SEK 60.3 M (60.8) 
    • Cash flow negative SEK 16.7 M (neg: 26.3)  
    • Order intake excl. service agreements SEK 213.7 M (211.0), of which RayStation SEK 191.8 M (193.4)

    SIGNIFICANT EVENTS DURING THE SECOND QUARTER 

    • RayStation was selected by a number of leading cancer clinics, including Johns Hopkins/Sibley Memorial Hospital, MedStar Georgetown University Hospital and Mayo Clinic Hospital in the US, the Academic Medical Center (AMC) in the Netherlands and Salzburger Landeskliniken (SALK) in Austria. 
    • All functionality in RayStation® 6 for Pencil Beam Scanning (PBS) can now also be used for Mitsubishi Electric’s PBS systems.  
    • Another six proton therapy centers opted for RayStation during the second quarter bringing the total number of proton therapy centers that have chosen RayStation to 35, representing more than half of all global proton therapy centers. 
    • A long-term collaborative agreement for RayCare* was signed with the University of Wisconsin-Madison. 
    • The company’s credit facility was increased from SEK 100 M to SEK 350 M. 

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    ABOUT RAYSEARCH
    RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

    More information about RaySearch is available at www.raysearchlabs.com. 

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO     Tel: +46 8 510 530 00  E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO                     Tel: +46 70 661 05 59  E-mail:
    peter.thysell@raysearchlabs.com 

    * Regulatory approval is required in some markets. 

    PDF

    MedStar Georgetown proton center selects RayStation

    PDF

    The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on the MEVION S250i Proton Therapy System[1] with HYPERSCAN when the facility opens for treatment later this year. The RayStation treatment planning system will enable the utilization of advanced IMPT capabilities that are unique to the HYPERSCAN technology, including multi-leaf collimation with Mevion’s Adaptive Aperture.

    The combination of RayStation and Mevion’s HYPERSCAN technology will enable clinicians at MedStar Georgetown to plan and treat patients with the advantage of very sharp field edges and minimized radiation to critical structures.

    Johan Löf, CEO of RaySearch, says: “The addition of support for HYPERSCAN in RayStation fits well with our commitment to supporting all modalities and vendors in the field of radiation therapy. With our ever-expanding toolset, we believe we are uniquely qualified and positioned to advance cancer treatment in order to improve outcomes for patients and support our customers and industry partners.”

    Joe Jachinowski, CEO of Mevion Medical Systems, says: “Mevion is looking forward to working with MedStar Georgetown and RaySearch to implement HYPERSCAN technology clinically. Our collaboration with RaySearch has been very productive and we are excited that everything has come together as planned.”

    About MedStar Georgetown University Hospital
    Learn more at:
    https://www.medstargeorgetown.org/our-services/cancer-care/why-choose-us/proton-beam

    About Mevion Medical Systems
    Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation therapy for cancer. Mevion is based in Littleton, Massachusetts, US, with a presence in the Europe, Japan and China. Learn more at:
    www.mevion.com.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare[2], which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    More information about RaySearch is available at
    www.raysearchlabs.com


    1
    MEVION S250i Proton Therapy System with HYPERSCAN has not been cleared by the USFDA for clinical use.
    2
    Subject to regulatory clearance in some markets.

     
    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com
     

    PDF

    RayStation and RayCare on show at AAPM, Denver

    PDF

    From 30 July–3 August, RaySearch will be exhibiting at the 59th AAPM Annual Meeting in Denver, Colorado. The company will demonstrate the innovative features in the latest release of its treatment planning system, RayStation®. In addition, RaySearch will give preview demonstrations of its forthcoming oncology information system, RayCare®*, which is due to be launched in December 2017. Attendees are welcome to visit RaySearch at booth #5079, and demonstrations can be booked now at www.raysearchlabs.com.

    New features in RayStation 6
    New functionality and a wide range of general improvements will all be on show. Major additions include support for TomoTherapy. RayStation will be the only system that enables planning for both conventional linacs and TomoTherapy systems, giving one point of control for all treatment planning activities.

    RayStation 6 also introduces simultaneous optimization of multiple beam sets for SMLC, DMLC and VMAT, and MR-based planning, which makes it possible to use an MR image as the planning image for photon therapy. Other highlights on show include Monte Carlo dose calculation for proton pencil beam scanning (PBS) and PBS planning with block apertures.

    Automated planning and Plan Explorer

    RayStation has extensive automated planning features that help optimize workflows and create new treatment possibilities. Plan Explorer, for example, makes it possible to automatically generate a large number of high-quality treatment plan alternatives, saving valuable time and giving the clinician a wide range of options to consider.

    Adaptive therapy

    RayStation is designed to make adaptive therapy easy to implement and perform in clinical practice. At the RaySearch booth, attendees can discover how automation features and smart tools in the fully integrated dose tracking and adaptive planning modules make it straightforward to get started.

    The next-generation OIS

    RayCare has been developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high-performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. 

    Evening symposium: Advancing cancer treatment through software innovation

    On Sunday 30 July from 6.30 pm, RaySearch will hold an evening symposium at the Grand Hyatt Denver, focused on how software is driving innovation in oncology. Moderator: Marc Mlyn, President, RaySearch Americas

    Symposium presentations:

    From history to future: Replacing a decade-old TPS with RayStation

    Dr. Shiva Das, Medical Physicist, UNC School of Medicine, Chapel Hill, NC, USA

    Fight cancer with code

    Johan Löf, Founder & CEO, RaySearch Laboratories AB, Stockholm, Sweden

    Registration for the symposium is open at: https://lnkd.in/ezDkpaS

    About RayStation

    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RayCare

    RayCare is a next generation OIS developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    About RaySearch

    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    More information about RaySearch is available at
    www.raysearchlabs.com 

    * Subject to regulatory clearance in some markets.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)

    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    Strong momentum in RayStation proton therapy sales

    PDF

    Eight additional proton therapy centers worldwide have chosen RayStation as their treatment planning system. Six of the orders were received in June 2017: the Children’s Cancer Hospital Foundation (Cairo, Egypt), Hospital Quirónsalud (Madrid, Spain); Mayo Clinic Hospital (Phoenix, US); ZON-PTC (Maastricht, Netherlands); MedStar Georgetown University Hospital (Washington DC, US) and the Johns Hopkins Medicine proton center at Sibley Memorial Hospital (Washington DC, US). RayStation was also recently selected by Tata Memorial Center in Mumbai, one of India’s first proton therapy facilities, and PLA General Hospital in Beijing, China. A total of 35 proton centers have purchased RayStation so far, and this constitutes more than half of the existing proton centers in the world.

    These eight centers represent a variety of hospital environments and machine types. RayStation will be used together with the IBA Proteus Plus and Proteus One systems, Mevion systems with HYPERSCAN, and Hitachi ProBeat systems.

    The centers will receive the latest version of RayStation, which includes innovative features such as fast Monte Carlo pencil beam scanning (PBS) optimization and dose calculation, use of PBS with apertures, and robust optimization/4D-CT optimization for proton and carbon ion planning. All purchases include both clinical and research licenses.

    RayStation has a wide range of features of value to researchers at academic centers. A few examples are LET and RBE calculations for proton and carbon PBS planning, interplay evaluation from machine delivery log files, PET-based range verification, proton and carbon planning on virtual CBCT(CT) images, and small animal X-ray irradiator planning.

    The clinical and research configurations of RayStation will be on show at the upcoming AAPM Annual Meeting in Denver, Colorado, 30 July–2 August 2017. Attendees are welcome to visit RaySearch at booth #5079 and demonstrations can be booked now at www.raysearchlabs.com.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    * Subject to regulatory clearance in some markets

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    RayStation selected for new Netherlands proton therapy center

    PDF

    The South-East Netherlands Proton Therapy Centre (ZON-PTC), located in Maastricht, has selected RayStation as its treatment planning system following an extensive evaluation of the leading software systems. Scheduled to open by early 2019, the new center will have a single-room setup utilizing the MEVION S250i Proton Therapy System with HYPERSCAN technology.

    Maria Jacobs, CEO of ZON-PTC and MAASTRO Clinic, says: “The initiative will enable patients in the Netherlands and beyond to benefit from this highly precise form of treatment. Our approach also demonstrates that technological innovation can be cost-effective. RayStation is an important aspect in this, combining advanced clinical functionality with an outstanding user experience to ensure smooth and efficient workflows.”

    The RayStation configuration will include pencil beam scanning, deformable registration, dose tracking, contouring and the full module for adaptive therapy. ZON-PTC is a joint undertaking between MAASTRO clinic and the Maastricht University Medical Centre (Maastricht UMC+). The state-of-the-art facility will deliver the benefits of proton therapy to patients across the southeast region of the Netherlands and will also be a referral site for hospitals across the country. The center expects to treat up to 400 patients per year.

    Geert Bosmans, Head of Clinical Proton Physics at ZON-PTC, says: “RayStation is the most advanced treatment planning system available and will give us wide-ranging clinical possibilities. ZON-PTC will be one of the first centers worldwide to combine RayStation and Mevion’s HYPERSCAN, and we look forward to collaborating on the implementation of all functionalities, including Adaptive Aperture. Fast calculation speed makes RayStation ideal when planning for complex cases, and it has the capabilities we need for efficient adaptive therapy, which is one of our priorities.

    Johan Löf, CEO of RaySearch, says: “RaySearch has a strong focus on proton therapy and we have designed RayStation to meet the demands of pioneering centers such as ZON-PTC. I am very pleased to support this outstanding collaboration, which will help to improve quality of life for many cancer patients.”

    About ZON-PTC
    The Southeast Netherlands Proton Therapy Center (ZON-PTC) is an initiative of MAASTRO Clinic and Maastricht UMC+. MAASTRO Clinic is a leading institute offering conventional radiation therapy with photons. Maastricht UMC+ is known both nationally and internationally for its focus on prevention and integrated approach to health care.
    ZON-PTC will benefit from the knowledge and expertise of both institutions and will share existing facilities.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    * Subject to regulatory clearance in some markets

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    PDF

    AMC, Netherlands, selects RayStation

    PDF

    The Academic Medical Center (AMC) in Amsterdam is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. To stay at the cutting edge in radiation therapy, the center needed a new treatment planning system, with key considerations including high calculation speed, automation capabilities, adaptive planning and a user-friendly interface. RayStation was selected following an evaluation of the leading systems.

    The purchase includes contouring, VMAT, IMRT, forward planning, adaptive and scripting. AMC will also become a reference center for RayStation’s Plan Explorer functionality. Plan Explorer makes it possible to automatically generate large numbers of plans for defined clinical goals and combinations of treatment techniques and machines.

    Professor Coen Rasch at AMC says: “Advances in treatment have placed increasing demands on treatment planning in recent years, and our existing system has struggled to keep up. To match the pace of new developments, AMC needs a user-friendly TPS where user interactions can be scripted. Automated planning is needed for most cases, so that clinicians can focus on the more complex treatment plans, and an excellent workflow for adaptive therapy is also essential. RayStation has the capabilities we need for fast and efficient workflows and advanced techniques, and will meet our changing needs into the future.”

    Johan Löf, CEO of RaySearch, says: “I am gratified to help AMC stay at the cutting edge of radiation therapy. Optimized workflows and efficient automation are key strengths of RayStation, and it is unmatched in support for adaptive therapy. I look forward to a long and successful cooperation.”

    About AMC
    The Academic Medical Center (AMC) is a leading Netherlands research institution and hospital. Over 7,000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching.
    AMC has 45 clinical and non-clinical departments, covering all the medical specializations recognized in the Netherlands. The hospital treats around 26,000 in-patients and 350,000 outpatients per year. A number of biotech companies (some of which are AMC spin-offs) are also located on the premises. This concentration of expertise makes the center a breeding ground for fruitful scientific collaboration.

    About RayStation
    RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

    * Subject to regulatory clearance in some markets

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00

    johan.lof@raysearchlabs.com

    PDF

    PBS planning for proton systems from Mitsubishi Electric now live in RayStation

    PDF

    With the release of a new service pack, RaySearch’s innovative radiation therapy treatment planning system, RayStation® 6, now supports pencil beam scanning (PBS) planning for proton therapy systems from Mitsubishi Electric. The service pack also includes several minor functionality improvements.

    All existing proton PBS functionality in RayStation can now be utilized for Mitsubishi Electric PBS machines. It is now possible, for example, to select the meterset rate to be used for each beam. Spot sorting and filtering is available during optimization, taking Mitsubishi Electric machine-specific scanning parameters into account during optimization for creation of deliverable plans. Range shifters can also be selected automatically during optimization if desired, securing optimal target coverage, and all Mitsubishi Electric PBS applicators are now supported.

    Johan Löf, CEO of RaySearch, says: “Proton therapy is an important focus area for RaySearch. We aim to support as many treatment machines as possible and help clinics to bring the benefits of this advanced technique to as many patients as possible.”

    PDF

    University of Wisconsin–Madison partners with RaySearch on next-generation OIS

    PDF

    The Department of Human Oncology at the University of Wisconsin-Madison has entered into an agreement with RaySearch to pioneer the RayCare® oncology information system. The groundbreaking system will be used in the department’s strong multidisciplinary approach to cancer care and its focus on cutting-edge techniques.

    RayCare facilitates comprehensive cancer treatment by unifying workflows for medical oncology, radiation oncology and surgical oncology. It helps promote a patient-centered approach to cancer treatment while increasing efficiency across the disciplines and meeting the demands of emerging techniques.

    The system will be co-developed at the University of Wisconsin—Madison and three satellite clinics, and should be prepared for clinical operation thereafter. Ultimately, all the University’s oncology activities will be assessed for coordination through RayCare. As the University has also selected RayStation® as its treatment planning system, the efficiency gains provided by the integration of RayStation and RayCare will be evaluated.

    John Bayouth, Chief of Radiation Oncology Physics at the UW-Department of Human Oncology, says: “As a forward-looking center, we are constantly exploring new ways to improve patient care. RayCare is being designed to coordinate our oncology disciplines and our hope is to realize the full potential of our diverse clinical resources.”

    Johan Löf, CEO of RaySearch, says: “The University of Wisconsin-Madison has a clear vision for the future of cancer treatment and research. RaySearch shares this vision, and I am proud to partner with them in developing an OIS that will extend their capabilities and help to keep them at the forefront.”

    PDF

    Leading Austrian clinic selects RayStation

    PDF

    Salzburg Country Hospitals–Paracelsus Medical University Hospital Salzburg (SALK) has selected the RayStation® treatment planning system, which it will use for photon therapy. The agreement covers three RayStation Planning licenses and five RayStation Doctor licenses, and functionality will include RayStation’s multi-criteria optimization.

    The Department of Radiotherapy and Radio-Oncology at the University Hospital Salzburg is an advanced clinic with a history of technical development, including its own treatment planning system and oncology information system and other innovations to benefit patients. RayStation will be used to plan for patients to be treated on Elekta linacs.

    Professor Felix Sedlmayer, head of the department, says: “We chose RayStation following a thorough evaluation of competing treatment planning systems. We are a clinic that aims to be at the forefront of medical technology, and RayStation will help us achieve our goals. It is a highly innovative system that supports the most advanced treatment techniques and will provide us with new treatment possibilities.” 

    Johan Löf, CEO of RaySearch, says: “I am delighted to support the future needs of SALK, a leading center that values innovation and prioritizes technology as a key factor in improving patient care. We have designed RayStation to meet the needs of clinics such as SALK, which work with advanced techniques. RayStation supports cutting-edge approaches and provides the best possible user experience for clinicians.”

    PDF

    RaySearch to show new software developments at AAMD Annual Meeting

    PDF

    June 11-15, RaySearch will be exhibiting at the American Association of Medical Dosimetrists (AAMD) annual meeting in Indianapolis, Indiana. The company will demonstrate the innovative features in the latest release of its treatment planning system, RayStation®. In addition, RaySearch will give preview demonstrations of its forthcoming oncology information system, RayCare®*, which is due to be launched in December 2017. Attendees are welcome to visit RaySearch at booth #216, and demonstrations can be booked now at www.raysearchlabs.com.

    RaySearch will also host treatment planning workshops on Tuesday 13 June, giving participants an in-depth, hands-on session with the software. The morning session is a general overview of the entire treatment planning system, while the afternoon session targets more advanced features such as deformable registration, treatment adaptation, Plan Explorer and more. 

    Clinical presentations
    Several RayStation customer clinics will make presentations during the meeting, including the following:

    Seattle Cancer Care Alliance Proton Therapy Center
    After the Plan: Using Templates and Scripts to Improve Documentation (Grayden MacLennan MBA, MSM, MS, CMD)

    Princeton-Procure Proton Therapy Center
    Introduction of Proton Planning (Kevin Sine, CMD, RT(R)(T))

    Seattle Cancer Care Alliance Proton Therapy Center
    Modern Pencil Beam Scanning Proton Therapy: Where We Are and Where We Are Going (Alexander Goughenour CMD)

    Northwestern Medicine Chicago Proton Center
    Proton Therapy Versus Photon Therapy: Which Treatment Sites Benefit from Which? (Stacey Schmidt BS, CMD, RT(T)

    New features in RayStation 6
    New functionality and a wide range of general improvements will all be on show at AAMD. Major additions include support for Helical TomoTherapy*. RayStation will be the only system that enables planning for both conventional linacs and Accuray TomoTherapy systems, giving one point of control for all treatment planning activities. 

    RayStation 6 also introduces simultaneous optimization of multiple beam sets for SMLC, DMLC and VMAT, and MR-based planning, which makes it possible to use an MR image as the primary data set for photon therapy. Other highlights include Monte Carlo dose calculation for proton pencil beam scanning (PBS) and PBS planning with block apertures. 

    PDF

    RaySearch founder Johan Löf nominated for global entrepreneurship award

    The winner of EY World Entrepreneur Of The Year, the premier international award for entrepreneurs, will be announced On 10 June. The finalist representing Sweden is Johan Löf, CEO and founder of RaySearch Laboratories AB, which develops innovative software that improves cancer treatment for millions of patients worldwide. Löf will compete against entrepreneurs from over 60 countries.

    EY Entrepreneur Of The Year celebrates successful entrepreneurs who stimulate economic growth. An independent national jury selected Löf as Sweden's representative in the international final, highlighting, achievements such as his founding of a company that benefits both individuals and society.

    The competition takes place in Monaco on 7-11 June. An independent international jury will name the winner on the evening of 10 June. Finalists are judged on six criteria: entrepreneurial spirit, economic development, strategic direction, impact on the wider world, innovation, and personal integrity and impact.

    When Johan Löf was 16, his mother died of lung cancer. Her death had a strong impact on his career choice. He founded RaySearch in 2000, based on discoveries he made during his PhD work at Karolinska Institutet in Sweden, and the company was listed in 2003. RaySearch’s main product today is RayStation®, an innovative system that enables cancer clinics to plan the optimal treatment approach for each patient. RayStation is used by over 400 cancer clinics around the world. RaySearch currently has around 220 employees, of whom 120 work with research and development.

    Carlos Esterling, who is responsible for EY Entrepreneur Of The Year in Sweden, said: “Johan Löf is the very image of an innovative entrepreneur. His amazing drive and exemplary leadership have led to great advances in cancer treatment both in Sweden and internationally. We at EY believe that entrepreneurs are essential for Sweden’s future, and our award recognizes role models who inspire others with the courage to pursue their ideas. I am proud that Johan will represent Sweden's outstanding entrepreneurship. His business is a world leader, and I believe he has an excellent chance in the final.”

    Johan Löf, CEO and founder of RaySearch, said: “It is a great honor to represent Sweden in the global final of this entrepreneurship award. I look forward to competing with my product, which improves quality of life for millions of patients. Being an entrepreneur means constantly creating new opportunities, and continued expansion is on the agenda for RaySearch. I am also extremely excited about this opportunity to meet entrepreneurs from all over the world.”

    Resolutions at the Annual General Meeting 2017

    PDF

    At the Annual General Meeting of RaySearch Laboratories AB (publ) held on May 23, 2017, the following resolutions were adopted.

    It was resolved that the accumulated profit, amounting to SEK 177,389,770 be brought forward and balanced in the new accounts.

    The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from personal liability.

    It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2018.

    It was resolved that remuneration to Board members who do not receive a salary from any Group company, amount to a total of SEK 980,000 for the period extending to the close of the next Annual General Meeting, of which SEK 480,000 to the Chairman and SEK 250,000 to each of the Board members elected by the Annual General Meeting, who do not receive a salary from any Group company.

    It was resolved that the Auditor’s fees be paid in accordance with current approved invoicing.

    It was resolved to re-elect Carl Filip Bergendal, Johan Löf and Hans Wigzell as Board members of the company, to elect Johanna Öberg as new board member and to appoint Carl Filip Bergendal as Chairman of the Board.

    It was resolved to re-elect the auditing firm Ernst & Young as Auditors, with the authorized public accountant Per Hedström as auditor in charge.

    It was resolved to authorize the Board to resolve on new issues of Series B shares and/or issues of convertible debt instruments, on one or several occasions up until the Annual General Meeting of 2018, in accordance with the proposal by the Board.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.  

    For more information about RaySearch, visit www.raysearchlabs.com.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com 

    PDF

    Interim report January 1 - March 31, 2017

    PDF

    RaySearch Laboratories AB (publ)

    “The positive trend continued in the first quarter and net sales increased 33 percent to SEK 127 M (95), of which revenues from RayStation® rose 39 percent to SEK 112 M (81), and operating profit rose 43 percent to SEK 33 M (23). MD Anderson has become collaboration partner regarding RayCare® and the development work is progressing as planned,” says Johan Löf, President and CEO of RaySearch. 

    THREE MONTHS (JANUARY-MARCH 2017) 

    • Net sales SEK 126.8 M (95.4), of which revenues from RayStation SEK 112.3 M (80.8) 
    • Profit after tax SEK 26.3 M (17.8), and earnings per share before/after dilution SEK 0.77 (0.52) 
    • Operating profit SEK 33.5 M (23.4) 
    • Cash flow negative SEK 3.0 M (neg: 5.2) 
    • Order intake excl. service agreements SEK 104.9 M (81.9), of which RayStation SEK 93.8 M (72.6) 
    • At the end of the period, order backlog for RayStation was SEK 58.1 M (47.1)

    SIGNIFICANT EVENTS DURING THE FIRST QUARTER 

    • RayStation 6 was launched*, making RayStation the only treatment planning system that can create plans for Accuray’s TomoTherapyTM treatment system, in addition to conventional linear accelerators. 
    • RayStation was chosen by several leading cancer clinics, including Nottingham City Hospital in the UK, Zhuozhou in China, the Tata Memorial Centre in India, Kennestone Hospital (part of WellStar Health System) and Sharp Memorial Hospital (part of Sharp HealthCare) in the US. In addition, among others, the Maryland Proton Treatment Center, in partnership with the University of Maryland, have expanded their RayStation installations. 
    • The University Health Network (UHN) in Canada has exclusively licensed a new artificial intelligence (AI) technology for automated radiation therapy treatment planning (AutoPlanning) to RaySearch. 
    • Long-term collaborative agreement with MD Anderson related to RayCare*. 
    • RaySearch’s CEO and founder, Johan Löf was named Sweden’s foremost entrepreneur in the Swedish final of the EY Entrepreneur of the Year 2016 competition. 

    * Regulatory clearance required in some markets

    NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    ABOUT RAYSEARCH
    RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
    More information about RaySearch is available at www.raysearchlabs.com. 

    FOR FURTHER INFORMATION, PLEASE CONTACT:
    Johan Löf, President and CEO                  Tel: +46 8 510 530 00           E-mail:
    johan.lof@raysearchlabs.com
    Peter Thysell, CFO                                    Tel: +46 70 661 05 59           E-mail: peter.thysell@raysearchlabs.com
     

    PDF

    RaySearch Annual Report for 2016

    PDF

    RaySearch Laboratories AB (publ) today published the English version of the Annual Report for 2016 on its website. The document also includes RaySearch’s corporate governance report.

    The Annual Report for the accounting period 1 January–31 December 2016 is now available at: www.raysearchlabs.com/investor

    Printed copies can be ordered by emailing a request to: ir@raysearchlabs.com

    As previously communicated, the RaySearch Annual General Meeting will be held on 23 May 2017 at 18:00 at RaySearch’s head office: Sveavägen 44, Stockholm, Sweden. The deadline for registration of attendance is 16.00 on 17 May 2017.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.

    More information about RaySearch is available at www.raysearchlabs.com

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    RaySearch Laboratories AB (publ) discloses the above information in accordance with securities market legislation. The information was first disclosed on 28 april 2017 at 10.00 CET.

    PDF

    Proton Monte Carlo dose calculation now part of RayStation

    PDF

    RayStation 6, the latest version of RaySearch’s innovative treatment planning system, introduces a Monte Carlo dose engine for proton pencil beam scanning (PBS) plans, which can be used in parallel with the existing pencil beam dose engine. The engine brings an additional level of precision without compromising on speed.

    Monte Carlo dose planning is one of the important new proton therapy features that RaySearch will be demonstrating this week at the PTCOG conference in Yokohama, Japan.

    Monte Carlo dose calculation is based on simulating the transport of individual particles. This makes it possible to fully account for the unaltered patient geometry, whereas analysis-based algorithms such as the pencil beam method require an approximate representation of the geometry. For the Monte Carlo method, accuracy is high, but speed was traditionally an issue until the advent of fast Monte Carlo algorithms. The dose engine in RayStation strikes the optimal balance between accurate physics modeling and speed, making it highly effective in clinical workflows.

    The Monte Carlo and pencil beam dose engines in RayStation are designed to be used in parallel, ensuring efficient and accurate dose calculation for all proton PBS planning needs. A single PBS machine model for a particular delivery system can support both the Monte Carlo and pencil beam dose calculations, and the beam-measurement data needed for commissioning is the same for both dose engines. The Monte Carlo and pencil beam dose engines can both be used for calculating spot dose distributions as input for optimization, with or without patient-specific block apertures, as well as for calculating a final dose distribution for plan approval.

    Johan Löf, CEO of RaySearch, says: “Proton therapy is an important area of focus for RaySearch and we aim to be at the leading edge of developments to improve patient treatment. The unmatched speed of RayStation makes it possible to deliver the accuracy of Monte Carlo dose planning while maintaining a fast and efficient clinical workflow.”

    PDF

    North American sales of RayStation continue to gain momentum

    PDF

    RayStation® is gaining an ever-stronger foothold in the North American market. Several leading treatment centers selected RayStation, or extended the clinical footprint of existing systems, in the first quarter of 2017. 

    Some of the most important of these facilities include:

    • Kennestone Hospital (a WellStar Health System facility) selected a full range of technologies, including Plan Explorer, an innovative tool to automatically prepare plans using several modalities to assess the best treatment approach.
    • Sharp Memorial Hospital (an affiliate within Sharp HealthCare) selected a broad range of technologies.
    • The Maryland Proton Treatment Center, in collaboration with the University of Maryland, extended its installation of RayStation, including additional clinical licenses for both photon and proton planning. RayStation will be used for pencil beam/IMPT planning on the Varian ProBeam system at MPTC.

      Katja Langen, PhD, Associate Chief of Medical Physics at MPTC, says: “We aim to provide world-class proton therapy to achieve the best possible outcomes for patients. To be at the cutting edge, we need access to the most advanced and innovative treatment planning technologies. We are excited to add RayStation to our treatment planning portfolio.”

    Marc Mlyn, President of RaySearch Americas, says: “RayStation is increasingly acknowledged as the most innovative and comprehensive treatment planning system on one platform, and we are excited about the continuing upward sales trend in North America. It is gratifying that so many leading centers are turning to RayStation for their treatment planning needs.”

    PDF

    TomoTherapy planning now live in RayStation

    PDF

    With the release of a new service pack, TomoTherapy planning is now available in RayStation® 6*, RaySearch’s innovative radiation therapy treatment planning system. The service pack includes several other functionality improvements.

    RayStation is now the only system to enable planning for both conventional linacs and TomoTherapy systems, giving clinics one point of control for all treatment planning needs. This is in line with RaySearch’s ambition to unify treatment planning as far as possible, eliminating the complications and additional steps that arise from using multiple software systems.

    TomoTherapy planning in RayStation is highly visual and intuitive to use, making it straightforward to achieve an optimal plan. At a glance, users can see MLC leaf shapes, jaw movements, estimated delivery time and other data that has previously not been immediately accessible. The user also has access to all RayStation’s advanced functionality, including multi-criteria optimization and adaptive planning. Optimization capabilities for the TomoTherapy machine include dynamic jaw support, delivery time constraints and the possibility to specify regions where irradiation is avoided. TomoTherapy planning can be smoothly integrated into the clinical workflow and treatment plans are sent to Accuray’s integrated data management system for delivery (IDMS 1.1 is required). 

    Other functionality added by the service pack includes manual editing of wave arcs for Vero machines and MR planning density view. MR-based planning is a new feature introduced in RayStation 6 that enables an MR-image to be used as the planning image.

    RayStation customers who use TomoTherapy systems have expressed great interest. Marie Tiffany, Clinical Scientist Radiotherapy Physics at Queen Elizabeth Hospital Birmingham, UK, says: “The versatility of TomoTherapy treatment delivery, combined with the advanced planning and evaluation tools in RayStation, will provide a powerful tool to treat the most complicated cancers.”

    Johan Löf, CEO of RaySearch, says: “Our vision is to bring harmony to treatment planning. TomoTherapy planning is an important step, and we will shortly be adding support for further systems and technologies. Unified treatment planning brings many benefits to clinics, including simplified workflows and reduced demands on staff training.”

    PDF

    RayStation and RayCare on show at ESTRO 36

    PDF

    During 6–8 May, RaySearch will be exhibiting at the ESTRO 36 congress in Vienna, Austria. The company will demonstrate the innovative features in the latest release of its treatment planning system, RayStation®. In addition, RaySearch will give preview demonstrations of its forthcoming oncology information system, RayCare®*, which is due to be launched in the second half of 2017. Attendees are welcome to visit RaySearch at booth #1600, and demonstrations can be booked now at www.raysearchlabs.com.

    New features in RayStation 6
    New functionality and a wide range of general improvements will all be on show. Major additions include support for the Accuray Radixact™ System*. RayStation will be the only system that enables planning for both conventional linacs and the Accuray TomoTherapy platform treatment delivery system, giving one point of control for all treatment planning activities. Björn Hårdemark, Deputy CEO of RaySearch, will present a preview of the system in the Accuray booth on Sunday, 7 May 1 from 16:05 to 16:25. Demonstrations can also be booked by visiting the RaySearch and Accuray booths.

    RayStation 6 also introduces simultaneous optimization of multiple beam sets for SMLC, DMLC and VMAT, and MR-based planning, which makes it possible to use an MR image as the planning image for photon therapy. Other highlights on show include Monte Carlo dose calculation for proton pencil beam scanning (PBS) and PBS planning with block apertures.

    Automated planning and Plan Explorer
    RayStation has extensive automated planning features that help optimize workflows and create new treatment possibilities. Plan Explorer, for example, makes it possible to automatically generate a large number of high-quality treatment plan alternatives, saving valuable time and giving the clinician a wide range of options to consider.

    Adaptive therapy
    RayStation is designed to make adaptive therapy easy to implement and perform in clinical practice. At the RaySearch booth, attendees can discover how automation features and smart tools in the fully integrated dose tracking and adaptive planning modules make it straightforward to get started.

    The next-generation OIS
    RayCare has been developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers. RayCare integrates the high-performance radiation therapy algorithms available in RayStation and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy.

    Lunch symposium: Advancing cancer treatment through software innovation
    On Saturday 6 May from 13.15–14.15, Room LEHAR 1–3, RaySearch will hold a lunch symposium focused on how software is driving innovation in oncology.

    Moderator: Simeon Nill, Head of Translational Radiotherapy Physics, Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

    Advancing cancer treatment through software innovation
    Johan Löf, Founder & CEO, RaySearch Laboratories AB, Stockholm, Sweden

    How to contribute to evidence-based radiotherapy in routine daily practice. From dream to reality.
    Johannes A. Langendijk, Professor and Chair of the Department of Radiation Oncology, University Medical Centre Groningen, Groningen, Netherlands

    Using RayStation as a unified treatment planning system to free up physicians’ time
    Xavier Mirabel, Professor and Chair of the Department of Radiation Therapy, Centre Oscar Lambret, Lille, France

    PDF

    RayStation selected for major new proton therapy center in China

    PDF

    RayStation will be the treatment planning system for a new proton center in Zhuozhou, Northern China, situated close to Beijing. Around 2,000 patients per year will be treated at Zhuozhou, which will be one of the biggest proton centers in the world. The center will be equipped with IBA’s Proteus®PLUS multi-room system; the setup includes five treatment rooms, four isocentric-gantry treatment rooms and a fixed-beam treatment room.

    The RayStation order, comprising eight clinical licenses, covers a range of advanced functionality, such as Monte Carlo dose calculation, robust optimization, proton PBS and DS planning, and fallback planning. Additional planning features for photon therapy will be included, such as 3D-CRT, IMRT, VMAT photon planning, and the system will also be used as a platform for research. Deployment of the treatment planning system is set to begin from August and clinical use will commence subject to regulatory clearance. 

    Olivier Legrain, CEO of IBA, says: “Our collaboration with RaySearch has enabled us to deliver a comprehensive solution that will give patients in Zhuozhou and the surrounding area access to the most advanced radiation therapy treatment available. IBA Proton Therapy systems, combined with RayStation, offer advanced functionality and unmatched usability to extend treatment possibilities.”

    Johan Löf, CEO of RaySearch, says: “It is very exciting to be part of this project to establish the first large proton center in a hospital environment in China. Proton therapy is taking off in China, and we aim to be at the forefront of developments. Together with IBA, we are able to deliver a complete platform that will optimize workflows and enable precise and personalized treatment.”

    PDF

    Share conversion in RaySearch Laboratories AB (publ)

    PDF

    In April 2017, 40,000 Class A shares were converted to Class B shares, at the request of a shareholder.
    The total number of votes in RaySearch thereafter amounts to 112,177,548 votes. The total number of registered shares in RaySearch amounts to 34,282,773 shares, out of which 8,654,975 are Class A shares and 25,627,798 are Class B shares.

    According to RaySearch Laboratories AB’s (publ) Articles of Association, owners of Class A shares have the right to have such shares converted to Class B shares. A conversion reduces the number of votes in the company. When a conversion has been carried out, RaySearch is obligated by law to disclose information on the changes occurred by the conversion.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.  

    For more information about RaySearch, visit www.raysearchlabs.com.

    For further information, please contact:
    Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
    Telephone: +46 (0)8-510 530 00
    johan.lof@raysearchlabs.com

    RaySearch discloses the information provided herein pursuant to the EU’s Market Abuse Regulation and the Securities Market Act.

    PDF

    Invitation to Annual General Meeting 2017

    PDF

    The shareholders in RaySearch Laboratories AB (publ), corporate identity no. 556322-6157, are hereby invited to the Annual General Meeting, to be held on Tuesday, 23 May, 2017, at 6:00 p.m., at the company’s offices at Sveavägen 44, 7th floor, Stockholm, Sweden.

    RIGHT TO PARTICIPATE AND NOTICE 

    Shareholders who wish to participate in the Annual General Meeting and to have the right to vote, must:

    - be recorded in the share register maintained by Euroclear Sweden AB not later than Wednesday, 17 May, 2017,

    - notify the company of their intention to participate in the Annual General Meeting by mail to RaySearch Laboratories AB (publ), P.O. Box 3297, 103 65 Stockholm, Sweden; by telephone +46 (0)8 510 530 00; by fax +46 (0)8 510 530 30; or by email to arsstamma2017@raysearchlabs.com, not later than Wednesday, 17 May, 2017, at 4:00 p.m. Assistants may accompany shareholders to the Meeting only if the shareholder has provided notice of the number of assistants, a maximum of two, in the manner described above for notification of participation. Notification should include the shareholder’s name, personal or corporate identity number, shareholding, address and telephone number.

    - at the Meeting be able to produce an ID-card valid in Sweden (e.g. passport, driver’s licence, national ID-card). Also, proxies and/or assistants must be able to produce an ID-card valid in Sweden (e.g. passport, driver’s license, national ID-card)as the case may be.

    Shareholders who have trustee-registered shares through a bank or broker, must request to temporarily register the shares in their own name with Euroclear Sweden AB to be entitled to exercise their voting rights at the Meeting. Such shareholders must inform the trustee of this request in adequate time prior to Wednesday, 17 May, 2017, when such registration must have been completed.

    POWER OF ATTORNEY ETC.

    If a shareholder intends to be represented by proxy, the shareholder must issue a written power of attorney, duly dated and signed. For practical reasons, the power of attorney should be submitted to the company in advance. Please note, however, that the original of any power of attorney must be presented at the Meeting and that it is therefore not sufficient to send it by fax or email. A power of attorney template is available on the company’s website, www.raysearchlabs.com, and will be sent at no cost to shareholders who request it and provide their postal address or email address. A power of attorney is valid no longer than one year from its issuance, unless a longer period of validity is expressly stated; however, in no event longer than five years. Representatives of legal entities must present a copy of a registration certificate or corresponding authorization document that indicates the authorized signatory.

    PROPOSED AGENDA 

    1. Opening of the Meeting.

    2. Election of a chairman of the Meeting.

    3. Preparation and approval of the list of shareholders entitled to vote at the Meeting.

    4. Election of one or two minute-checkers.

    5. Approval of the proposed agenda.

    6. Determination whether the Meeting has been duly convened.

    7. Address by the CEO.

    8. Presentation of the Annual Report and the Auditors’ Report as well as the consolidated financial statements and the Auditors’ Report for the consolidated financial statements for the 2016 fiscal year.

    9. Resolutions concerning
      a)          the adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet;
      b)          the disposition to be made of the company’s profits or losses as shown in the balance sheet adopted by the Meeting;
                   and
      c)          the discharge of the members of the Board and of the CEO from personal liability.

    10. Resolution on guidelines for remuneration to senior executives.

    11. Determination of the number of members of the Board and deputies.

    12. Determination of the fees to be paid to the Board and auditors.

    13. Election of the members of the Board (including Chairman) and deputy member(s) of the Board.

    14. Election of auditor.

    15. Resolution on the authorization to the Board to resolve on new issues of Series B shares and/or issues of convertible debt instruments.

    16. Close of the Annual General Meeting.

    PROPOSED DECISIONS 

    Election of a chairman of the Meeting (item 2)

    The Board proposes that Carl Filip Bergendal be appointed chairman of the Meeting.

    Disposition of earnings (item 9 b)

    As the company is currently in a phase of rapid expansion that requires access to capital, the Board and the CEO propose that no dividend be paid to the company's shareholders. The accumulated profit of SEK 177,390,000 is proposed to be brought forward and balanced in the new accounts.

    Guidelines for remuneration to senior executives (item 10)

    The Board proposes the Meeting to adopt the following guidelines for remuneration to senior executives to apply for the period until the close of the Annual General Meeting of 2018.

    Salary and other remuneration

    The CEO shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to 2.0 per cent of the Group’s earnings before tax after allocations to the profit-sharing foundation RayFoundation, though not more than 12 months’ salary. In addition, the CEO may have other benefits of a common nature, such as a company car.

    The CEO’s salary shall be reviewed annually. This shall take place through negotiations between the CEO and the Chairman of the Board, after which the Chairman shall present a proposal to the other Board members. The CEO shall not be present when the Board discusses and resolves on this issue.

    The other senior executives are the Deputy CEO, Chief Financial Officer (CFO), Director of Research, Director of Development, Director of Sales and Marketing, Director of Sales for the Asia & Pacific region, Director of Service and the General Counsel. The other senior executives shall, as all other employees in RaySearch Laboratories AB (publ) except the CEO, be covered by the profit-sharing foundation RayFoundation, and thereby receive a variable remuneration. Furthermore, the following shall apply with regard to remuneration to the other senior executives.

    The Director of Sales and Marketing shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation® worldwide.

    The Director of Sales for the Asia & Pacific region shall receive a fixed salary and a variable remuneration. The variable remuneration shall amount to a certain percentage of the sales of RayStation® in the Asia & Pacific region.

    The Deputy CEO, CFO, Director of Research, Director of Development, Director of Service, and the General Counsel, shall receive a fixed salary but no variable remuneration, other than being covered by the profit-sharing foundation RayFoundation in accordance with the above.

    The salaries of the other senior executives shall also be reviewed annually. This shall take place in negotiations between the CEO and each individual.

    Incentive programs

    There are no incentive programs intended specifically for senior executives and none is proposed. However, the senior executives, except the CEO, may participate together with the other employees in such option programs and profit-sharing programs as the company may apply.

    Pensions

    All pension undertakings are defined-contribution plans. The retirement age for the CEO and the other senior executives is 65 years and the pension premiums correspond to the Swedish ITP plan.

    Period of notice

    If the CEO terminates his employment, his period of notice is 6 months, and if the company terminates the CEO’s employment, the period of notice is 12 months. In both cases, the CEO is entitled to salary during the period of notice. In respect of the other senior executives there is a mutual period of notice of 3 months during which salary shall be paid.

    Severance pay

    Neither the CEO nor the other senior executives shall be entitled to any severance pay, in a formal sense, should their employment cease. However, as described above, the CEO and the other senior executives shall be entitled to salary during the period of notice.

    Deviation

    The Board proposes that the Board be entitled to deviate from the above guidelines if there are special reasons for such deviations.

    Number of members of the Board and deputies (item 11)

    Shareholders representing approximately 66 percent of the total number of votes in the company propose that the number of Board members be 4, with no deputies.

    Fees (item 12)

    Shareholders representing approximately 66 percent of the total number of votes in the company propose:

    that remuneration to Board members who do not receive a salary from any Group company, amount to a total of SEK 980,000 for the period extending to the next Annual General Meeting, of which SEK 480,000 to be paid to the Chairman and SEK 250,000 to each of the Board members elected by the Annual General Meeting, who do not receive a salary from any Group company.

    that the auditors’ fees shall be paid in accordance with current approved invoicing. 

    Board, etc. (item 13)

    Shareholders representing approximately 66 percent of the total number of votes in the company propose:

    that  Carl Filip Bergendal, Johan Löf and Hans Wigzell be re-elected as Board members in the company;

    that Johanna Öberg be elected as Board member in the company; and 

    that Carl Filip Bergendal be elected as Chairman of the Board. 

    Election of auditor (item 14)

    The Board proposes that the auditing firm Ernst & Young be appointed as auditors, with the authorized public accountant Per Hedström as auditor in charge.

    Resolution on the authorization to the Board to resolve on new issues of Series B shares and/or issues of convertible debt instruments (item 15)

    The Board proposes that the Meeting authorize the Board to, on one or several occasions up until the next Annual General Meeting, resolve on new issues of Series B shares and/or issues of convertible debt instruments convertible into Series B shares. The Board’s resolutions on issuing shares and/or convertible debt instruments may lead to an increase in the number of shares in the company representing a maximum of 10 per cent of the registered share capital per the date of this invitation, amounting to SEK 17,141,386.50, however, not exceeding the number of shares and share capital according to the company's articles of association at the time of such resolution. At the date of this invitation, such maximum increase represents an increase of approximately 2.6 per cent of the total number of votes in the company. Issues made by virtue of this authorization may be made with or without deviation from the shareholders’ pre-emption right in accordance with Chapter 13, Section 1, item 2 c and Chapter 15, Section 1, item 2 c of the Swedish Companies Act, and, other than against payment in cash, with or without terms of issue in kind or set-off or other terms as stated in Chapter 13, Section 5, first paragraph, item 6 and Chapter 15, Section 5, first paragraph, item 4 of the Swedish Companies Act.

    The purpose of the authorization is to increase the company’s financial flexibility. In the event of deviation from the shareholders’ pre-emption right, the subscription price shall be on market terms. Other terms may be resolved by the Board.

    A valid resolution requires that the proposal be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the Meeting.

    NUMBER OF SHARES AND VOTES AND INFORMATION ON HOLDING OF OWN SHARES
    The total number of shares in the company at the date of this invitation is 34,282,773, of which 8,654,975 are Series A shares and 25,627,798 are Series B shares, which means that there are a total of 112,177,548 votes in the company. The company holds no own shares.

    AVAILABILITY OF DOCUMENTS AND OTHER ISSUES
    The Annual Report, the Auditor’s Report in accordance with Chapter 8, Section 54 of the Swedish Companies Act and the Board’s complete proposals in accordance with the above will be held available at the company’s offices and on the company’s website no later than from and including 2 May, 2017, and will be sent to those shareholders who have provided notice that they wish to receive such information from the company.

    For the abovementioned decisions, the support of shareholders representing more than half of the votes cast is necessary, except in relation to item 15 for which a qualified majority is necessary, as specified in item 15 above. 

    THE RIGHT OF THE SHAREHOLDERS TO REQUEST INFORMATION
    The shareholders have the right at the Annual General Meeting to request that the Board and the CEO provide information about facts that can affect the assessment of an item on the agenda and facts that can affect the assessment of the economic situation of the company. Such information shall be provided if it can be done without substantial harm to the company. The obligation to inform also applies in respect of the company’s relationship to other Group companies, the consolidated financial statements and facts according to the above in respect of subsidiaries.

    *********

    Stockholm, April 2017

    Board of Directors

    PDF

    Nottingham City Hospital, UK, Selects RayStation

    PDF

    Nottingham City Hospital in the UK has chosen RayStation as the new treatment planning system for its radiation therapy department. The department treats patients using Elekta linacs and an Accuray TomoTherapy system.

    The Nottingham Radiotherapy Service is the specialist treatment center for Nottinghamshire and the East Midlands. The department has invested heavily in new technology and equipment in order to provide the best possible treatment for patients. Techniques offered include VMAT, image-guided radiation therapy (IGRT), Papillon (contact brachytherapy) and selective internal radiation therapy (SIRT). Nottingham City Hospital is a stereotactic radiosurgery referral site and receives referrals from many hospitals across the region.

    RayStation will replace separate software applications currently being used for virtual simulation, deformable registration, auto-segmentation and VMAT planning. The system will enable the hospital to implement adaptive therapy, and its fast computation speed will significantly reduce planning time.

    Keith Langmack, Head of Radiotherapy Physics at Nottingham City Hospital, says: “RayStation will consolidate the functionality of several different systems, giving us a smooth, integrated workflow. It can support both linacs and TomoTherapy systems and offers outstanding support for adaptive planning and automation. After a thorough evaluation of alternative systems, RayStation clearly had the edge.”

    Johan Löf, CEO of RaySearch, says: “Nottingham City Hospital is a leading UK center. It is highly gratifying to help them replace multiple systems, unify treatment planning and increase automation – all of which are key strengths of RayStation.”

    PDF

    RaySearch enters collaboration with premier US cancer center regarding RayCare

    PDF

    The University of Texas MD Anderson Cancer Center in Houston, Texas, will collaborate with RaySearch on the development of RayCare®*, the next-generation oncology information system designed for the clinical workflow needs of today and tomorrow. The agreement covers all of MD Anderson’s sites in the Greater Houston area, including five regional cancer centers. One goal of the collaboration is to enable clinical implementation of RayCare in a complex and large-scale environment.  

    MD Anderson is one of the world’s largest cancer centers and a global leader in clinical research. The center treats around 130,000 patients per year and has over 20,000 employees. The scale of its operations makes efficiency and safety key priorities, and these will be significant strengths of the RayCare system.

    RayCare is designed to unify and consolidate the different software systems that are commonly in operation, including systems for medical oncology, radiation oncology and surgical oncology. Integrating the varied activities in these workflows saves time, reduces complication and minimizes the risk of errors that can occur when transferring information between systems. Potential benefits for patients include a smoother treatment experience and better continuity of care.

    This is the next step in a strong strategic collaboration that combines the research and development strengths of MD Anderson and RaySearch, with the aim of converting research findings into practical solutions that can be brought to market quickly for the benefit of cancer clinics everywhere. MD Anderson has also started using RayStation® to generate clinical treatment plans. This is the first phase of a planned clinical rollout that follows extensive training of the clinical teams. RayStation and RayCare are designed to integrate seamlessly, paving the way for even greater gains.

    Johan Löf, CEO of RaySearch, says: “I am proud that MD Anderson Cancer Center has joined us in the RayCare project. Solving the coordination, safety and efficiency needs of one of the world’s largest cancer care providers is one of our most exciting challenges to date. This collaboration has a strong foundation for success, building on the vast clinical knowledge and resources of MD Anderson and the innovative development capabilities of RaySearch.”

    PDF

    RaySearch Laboratories AB (publ) Year-end Report 2016

    PDF

    “A strong fourth quarter ended a new record year. In 2016, net sales rose 34 percent to SEK 531 M (398), of which revenues from RayStation® rose 58 percent to SEK 476 M (300), and operating profit rose 109 percent to SEK 200 M (95). The development of RayCare®* is continuing as planned,” says Johan Löf, President and CEO of RaySearch.

    FOURTH QUARTER (OCTOBER-DECEMBER, 2016) 

    • Net sales SEK 191.4 M (132.0), of which revenues from RayStation SEK 174.8 M (109.4) 
    • Profit after tax SEK 75.9 M (33.3), and earnings per share before/after dilution SEK 2.21 (0.97) 
    • Operating profit SEK 100.2 M (44.3) 
    • Cash flow SEK 56.6 M (12.4) 
    • Order intake excl. service agreements SEK 189.0 M (117.9), of which RayStation SEK 176.3 M (102.9)  
    • Order backlog for RayStation was SEK 67.5 M (49.1) at the end of the period

    TWELVE MONTHS (JANUARY-DECEMBER, 2016) 

    • Net sales SEK 531.5 M (397.6), of which revenues from RayStation SEK 476.0 M (300.4) 
    • Profit after tax SEK 151.4 M (70.2), and earnings per share before/after dilution SEK 4.42 (2.05) 
    • Operating profit SEK 200.0 M (95.3) 
    • Cash flow SEK 26.2 M (3.6) 
    • Order intake excl. service agreements SEK 501.1 M (385.2), of which RayStation SEK 461.0 M (316.9)  
    • The Board of Directors proposes that no dividend be paid for 2016

    SIGNIFICANT EVENTS DURING THE FOURTH QUARTER 

    • RaySearch secured several major orders, including Chang Gung Memorial Hospital (Kaohsiung) in Taiwan and the University of Washington Medical Center, University of Wisconsin-Madison and University of Arizona Radiation Oncology (Tucson) in the US. 
    • Erik Hedlund resigned from his position as Chairman of the Board and left the Board on November 17, 2016. Carl Filip Bergendal was elected new Chairman until the Annual General Meeting on May 23, 2017. 
    • In December, 1,567,089 Class A shares were converted to Class B shares at the request of shareholders. 

    SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD 

    • RayStation 6 was launched* and is the only treatment planning system that can create plans for both conventional linear accelerators and Accuray’s TomoTherapyTM treatment system. 
    • University Health Network (UHN) in Canada exclusively licensed a new artificial intelligence (AI) technology for automated radiation therapy treatment planning (AutoPlanning) to RaySearch. 
    • RaySearch’s CEO and founder, Johan Löf was named Sweden’s foremost entrepreneur in the national final of the EY Entrepreneur of the Year competition. 

    ABOUT RAYSEARCH 

    RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003. More information about RaySearch is available at www.raysearchlabs.com. 

    FOR FURTHER INFORMATION, PLEASE CONTACT: 

    Johan Löf, President and CEO
    Tel: +46 8 510 530 00
    Email:
    johan.lof@raysearchlabs.com 

    Peter Thysell, CFO
    Tel: +46 70 661 05 59
    Email: peter.thysell@raysearchlabs.com
     

    The information contained in the interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU’s Market Abuse Regulation and the Securities Market Act. The information was submitted for publication on February 17, 2017 at 7:45 a.m. CET.

    *Regulatory approval is required in some markets.

    PDF

    RaySearch postpones the interim report for the first quarter of 2017 because of CEO’s participation in the trade fair PTCOG in Japan

    PDF

    RaySearch Laboratories AB (publ) postpones the interim report for the first quarter of 2017 to 19 May 2017 at 07:45 CET, since the company’s CEO will attend the trade fair PTCOG in Japan on 8-13 May (and thus cannot attend a board meeting in connection with the previously announced date of that report).

    RaySearch’s year-end report for 2016 will be released on 17 February 2017 at 07.45 CET as previously announced.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.  

    For more information about RaySearch, visit www.raysearchlabs.com.

    For further information, please contact:
    Johan Löf, CEO              Telephone: +46 8 510 530 00     Email: johan.lof@raysearchlabs.com 
    Peter Thysell, CFO         Telephone: +46 70 661 05 59     Email: peter.thysell@raysearchlabs.com

    PDF

    Taiwan’s Chang Gung Memorial Hospital selects RayStation for proton therapy

    PDF

    Chang Gung Memorial Hospital, a leading teaching hospital in Kaohsiung, Taiwan, has chosen RayStation as the treatment planning system for use with its new Sumitomo proton therapy system.

    Established in 1976, the hospital has expanded rapidly and is now one of Taiwan’s foremost centers for treatment and research. The Proton and Radiation Therapy Center of Chang Gung Memorial Hospital was the first proton center in Taiwan, and the center provides advanced radiation therapy services to patients from Taiwan and internationally. Annually, it treats around 3,000 patients with photon radiation and 1,500 patients with protons.

    The RayStation order, which was placed via Sumitomo Heavy Industries, comprises software, computer hardware, beam commissioning, user training and clinical licenses. Delivery is scheduled for August 2017, and commissioning will also take place during the year. The hospital expects to begin treating patients using the system in early 2018.

    Kazuto Kaneshige, Senior Vice President, Sumitomo Heavy Industries, Ltd., says: “Sumitomo is very happy to supply RayStation to Chang Gung Memorial Hospital. RayStation will accommodate the hospital’s requirements and make it possible to fully exploit the capabilities of our proton therapy system.”

    Johan Löf, CEO of RaySearch, says: “I am delighted to be able to support the proton planning needs of Chang Gung Memorial Hospital, which is a pioneer of cutting-edge techniques in Taiwan. Asia is a technologically advanced market and an important focus for RaySearch. We have a strong presence in the region, supporting a variety of different treatment machines, and we will continue to extend our partnerships with leading cancer centers.”

    PDF

    University of Washington Medical Center selects RayStation

    PDF

    The Department of Radiation Oncology at UW Medical Center has purchased RayStation®, which will become its primary clinical radiation therapy treatment planning system and research platform in 2017.

    RayStation will be used for all external beam treatment planning at the University of Washington. The system will feature several advanced functionalities, including adaptive planning, deformable registration, fallback planning and the unique Plan Explorer tool.  Plan Explorer enables automatic generation of a large number of high-quality treatment plans for different treatment techniques and types of machines, based on selected clinical goals.

    The university also plans to continue its internal development of neutron planning, utilizing the research and interface tools in RayStation.

    Johan Löf, CEO of RaySearch Laboratories, says: “UW Medical Center is a cutting-edge cancer center. Its pioneering focus is a perfect match for RayStation, which supports the most advanced techniques and technologies across a variety of different machines. We are delighted to be a partner in advancing both treatment and research.”

    PDF

    University of Arizona Radiation Oncology (Tucson) selects RayStation

    PDF

    The Department of Radiation Oncology at the University of Arizona and Banner Health has purchased RayStation®, which will become the primary clinical radiation therapy treatment planning system at both the Main Campus location and the Orange Grove Campus facility.

    RayStation will be used for all external beam treatment planning at the University of Arizona. It was purchased in part to support the new expansion to the University of Arizona Cancer Center at the North Campus location, which will be completed in the fall of 2017. This 20,000-square-foot expansion will house a radiation oncology facility with state-of-the-art precision technology, including the new RayStation treatment planning system.

    Baldassarre Stea, MD PhD, Professor and Department Head of Radiation Oncology, says : “Our goal is to build a comprehensive facility that provides advanced technologies for our patients at every level. We believe that the choices we have made will help us achieve our vision of providing this highest quality of care. As the only NCI-designated Comprehensive Cancer Center in the State of Arizona, we wanted to select a treatment planning system that offered cutting-edge tools and the ability to support research and clinical trials. We look forward to working with RaySearch.”

    Johan Löf, CEO of RaySearch, says: “This is an exciting partnership with great potential. The University of Arizona has an ambition to provide the highest level of care through advanced technology, and RayStation supports the latest techniques across the spectrum of treatment delivery machines. We are well positioned to meet the university’s treatment planning needs into the future.”

    PDF

    RaySearch CEO and founder Johan Löf named Swedish entrepreneur of the year

    PDF

    On Wednesday 1 February, RaySearch CEO Johan Löf was honored as Sweden’s foremost entrepreneur in the national final of the EY Entrepreneur Of The Year competition, sponsored by Ernst & Young, at a gala event hosted at Stockholm City Hall. He will now represent Sweden in the global final in June, when the world’s top entrepreneur will be selected.

    The jury’s motivation for the choice stated: “Johan Löf has created a company that benefits both individuals and society. Advanced products and strong personal and commercial drive make his business stand out. Continued expansion is on the agenda for this entrepreneur, who improves quality of life for millions of people.”

    Johan Löf started the medical technology company RaySearch in 2000, based on his PhD work at Karolinska Institutet in Stockholm on optimization of radiation therapy. Today, the company has over 200 employees and 2016 sales were SEK 531 million.

    RaySearch’s treatment planning software, RayStation®, makes it possible to analyze a tumor and surrounding healthy tissue and calculate the optimal radiation treatment for each individual cancer patient. RayStation is the most advanced treatment planning system on the market. It supports the latest clinical techniques and makes the planning process faster and simpler.

    Carlos Esterling, who is responsible for EY Entrepreneur Of The Year in Sweden, said: “Johan Löf is the very image of an innovative entrepreneur. His amazing drive and exemplary leadership have led to major advances in cancer care, both in Sweden and internationally. Johan is a worthy winner and, given that his business is a world leader, I think he has great chances in the global final this summer.”

    Johan Löf, CEO of RaySearch, said: “This award is a tremendous honor. RaySearch is very much a team effort, and I would like to thank the talented and dedicated co-workers in the company who have made this success possible. Being an entrepreneur means constantly moving forward and creating new possibilities. Towards the end of this year, we will release a next-generation oncology information system, RayCare®. This will, among other things, allow us to take a holistic approach to cancer treatment and expand our application to adjacent fields such as surgery and chemotherapy. This is just the beginning for RaySearch.”

    PDF

    RaySearch licenses AI technology for automated treatment planning from UHN

    PDF

    University Health Network (UHN) in Canada has exclusively licensed a new artificial intelligence (AI) technology for automated radiation therapy treatment planning to RaySearch, for incorporation* into the RayStation® treatment planning system. The technology was developed by the Techna Institute, which is a collaboration between UHN and the University of Toronto.

    The license gives RaySearch the ability to integrate deep-learning algorithms from Princess Margaret Cancer Centre's AI automated planning technology platform into RayStation. The technology will be built into RayStation’s module for automated treatment planning across multiple treatment sites, enabling rapid adoption by clinical customers.

    Princess Margaret Cancer Centre has been developing AI technologies to automate radiation therapy processes over the last several years. AutoPlanning, developed by Physicist Dr. Tom Purdie and Researcher Dr. Chris McIntosh at Princess Margaret, provides a fundamentally different paradigm for generating radiation therapy treatment plans compared with both current manual and automated methods. Conventional methods have focused on learning a few treatment parameters, whereas AutoPlanning learns to model the shape and intensity of the radiation treatment as it is related to the patient’s images, reducing planning times from hours to minutes, while requiring minimal upfront preparation or user interaction.

    The AutoPlanning AI technology uses customized machine learning and image processing to determine the relevant features of treatment plans and learn quantitative relationships between patients in order to create radiotherapy treatment plans. Specifically, it utilizes a database of thousands of high-quality plans to generate optimal solutions to the planning problem.

    Dr. Tom Purdie of Princess Margaret Cancer Centre, says: “AutoPlanning has a machine-learning engine that automatically learns from previous plans and determines what the best plan for a new patient is supposed to look like. The license to RaySearch will make AutoPlanning available to hospitals across the globe, allowing them to create better plans more efficiently.”

    Johan Löf, CEO of RaySearch, says: “This technology has the potential to make a huge contribution to patient care. I am delighted to be able to bring its benefits to centers around the world as part of the RayStation platform. This development fits perfectly with our strong focus on advanced automation features in RayStation.”

    * Subject to regulatory clearance in some markets

    PDF

    RaySearch increases the operating profit by 126 percent in the fourth quarter

    PDF

    RaySearch Laboratories AB (publ) releases preliminary numbers for the fourth quarter and the full-year 2016 earlier than the year-end report due to the strong increase in the operating profit.

    Sales increased by 45 percent to 191 (132) MSEK in the fourth quarter and the operating profit increased by 126 percent to 100 (44) MSEK.

    Sales for the full-year increased by 34 percent to 531 (398) MSEK and the operating profit increased by 109 percent to 200 (95) MSEK.

    The above numbers are preliminary and a final year-end report will be released on 17 February 2017 at 07.45 CET as previously announced.

    About RaySearch
    RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation® treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.  

    For more information about RaySearch, visit www.raysearchlabs.com.

    For further information, please contact:
    Johan Löf, CEO              Telephone: +46 8 510 530 00     Epost: johan.lof@raysearchlabs.com
    Peter Thysell, CFO         Telephone: +46 70 661 05 59     Epost: peter.thysell@raysearchlabs.com 


    This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 22.30 CET on 31 January 2017.

    PDF

    New RayStation release to include TomoTherapy planning

    PDF

    RayStation® 6*, the latest release of RaySearch’s innovative radiation therapy treatment planning system, adds significant new functionality and a wide range of general improvements. Major additions include forthcoming support for Accuray TomoTherapy™ systems.

    The new release sets RayStation apart as the only system to enable planning for both conventional linacs and TomoTherapy systems, giving clinics one point of control for all treatment planning needs. This is in line with RaySearch’s ambition to unify treatment planning as far as possible, eliminating the complications and additional steps that arise from using multiple software systems. All contouring work can be done in one workspace. It is also possible to plan combined treatments and accurately calculate combined dose. Clinical support for TomoTherapy systems is pending final validation and will be included in a service pack to be released in the near future.

    Other RayStation 6 highlights include:

    • Monte Carlo dose calculation for proton pencil-beam scanning (PBS)
    • PBS planning with block apertures
    • Simultaneous co-optimization of multiple beamsets
    • MR-based planning, using MR-image as planning image
    • Auto-recovery

    RayStation 6 also includes many other additions and general improvements, such as a new dose brush tool to adjust dose in user-specified regions, dose thumbnails in Plan Explorer, support for patients scanned decubitus left/right, the ability to change patient ID, improved prescribed fraction dose handling and display, as well as further enhancements to the GUI.

    Johan Löf, CEO of RaySearch, says: “Our vision is to bring harmony to treatment planning. TomoTherapy planning is an important step, and we will shortly be adding support for further systems and technologies. Unified treatment planning brings many benefits to clinics, including simplified workflows and reduced demands on staff training.”

    * Subject to regulatory clearance in some markets

    PDF

    University of Wisconsin-Madison selects RayStation

    PDF

    The Department of Human Oncology at the University of Wisconsin-Madison has chosen RayStation® as its next radiation therapy treatment planning system. The agreement was signed in late December 2016, and the purchase is planned to occur in two phases.

    RayStation will be used for external beam treatment planning at the University of Wisconsin and satellite clinics. The agreement also covers affiliates and other partnerships.  The purchase includes advanced features such as deformable registration, dose accumulation and adaptive radiation therapy planning. The university will also be an early investigator of TomoTherapy™ planning* in RayStation, which allows for single-platform planning including the Accuray TomoTherapy machines.

    John Bayouth, Chief of Radiation Oncology Physics at the Department of Human Oncology, says: “The university is constantly developing and extending its capabilities in the realm of radiation therapy treatment planning.  Our intention is to explore plans that leverage the diversity of treatment delivery technologies in our system and determine the optimal approach for each patient.”

    Johan Löf, CEO of RaySearch Laboratories, says: “The University of Wisconsin-Madison is well known for its capabilities and long track record in radiation treatment of cancer. The university has conducted pioneering research since the advent of three-dimensional patient imaging and has also spawned several successful companies within treatment planning and delivery. We share a spirit of innovation, and our relationship will lead to further advancement of cancer care. This order, and over 40 more RayStation orders that we received during the fourth quarter, contributed to a very strong finish for 2016.”

    * Subject to regulatory clearance in some markets

    PDF